Emily Minkow

Emily Minkow is a Venture Partner at RA Capital, where she focuses on creating and leading new biotech companies.  Since joining RA, Emily has served as Interim CEO of Stylus Medicine, a stealth-stage genome engineering company, and contributed to the founding of and investment in several other companies in the genetic medicine, rare disease, immunology, and oncology spaces. Prior to joining RA, Emily was Chief Business Officer of Prevail Therapeutics, a gene therapy company focused on genetic forms of neurodegenerative disease, from the company’s inception through its IPO and its acquisition by Eli Lilly in 2021. Previously, Emily spent over seven years at Celgene Corporation in positions of increasing responsibility in business development, in global marketing for the launch of Otezla for psoriasis and psoriatic arthritis, and as Principal to the Chairman and CEO. Emily started her career in strategy consulting at Frankel Group. She received a BA from Princeton University and an MBA from Harvard Business School.